Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human breast cancer and ovarian cancer xenografts

Investigational New Drugs

Volumn 20, Issue 3, 2002, Pages 241-251

  Teicher, Beverly A ^a   Menon, Krishna ^a   Alvarez, Enrique ^a   Shih, Chuan ^a   Faul, Margaret M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antiangiogenic agent; Intratumoral vessels; MX 1 breast carcinoma xenograft; Ovarian cancer xenograft; Protein kinase C (PKC ); SKOV 3

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIGEN; ANTINEOPLASTIC AGENT; BISINDOLYLMALEIMIDE; CARBOPLATIN; CD31 ANTIGEN; COMPOUND 317615; ENDOGLIN; FLUOROURACIL; GEMCITABINE; PACLITAXEL; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; 317615 X 2HCL; ALKYLATING AGENT; ENZYME INHIBITOR; ORGANIC COMPOUND; PROTEIN KINASE C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LIFESPAN; MOUSE; NONHUMAN; OVARY CARCINOMA; PERITONEUM TUMOR; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SUBCUTANEOUS TISSUE TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASCULAR ENDOTHELIUM; ANIMAL; BLOOD FLOW; BREAST TUMOR; CANCER TRANSPLANTATION; DRUG ANTAGONISM; DRUG EFFECT; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; VASCULARIZATION; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMAL; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CARBOPLATIN; CELL SURVIVAL; ENZYME INHIBITORS; FEMALE; HUMAN; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN KINASE C; REGIONAL BLOOD FLOW; TRANSPLANTATION, HETEROLOGOUS; ANIMALS; HUMANS; ORGANIC CHEMICALS;

EID: 0036021216     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016297611825     Document Type: Article

References (71)

1. Neoplasms of the breast
2. The estrogen receptor: A logical target for the prevention of breast cancer with antiestrogens
3. Adjuvant therapy for breast cancer
4. Primary systemic therapy in operable breast cancer
5. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer
6. Ovarian cancer
7. The role of gemcitabine in the treatment of ovarian cancer
8. Second-line treatment of ovarian cancer
9. The genetics, screening and treatment of epithelial ovarian cancer: An update
10. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - A new standard of care?
11. Oral etoposide for the treatment of recurrent ovarian cancer
12. Progress in the treatment of ovarian cancer
13. Oxaliplatin in ovarian cancer
14. Interating radiation therapy in the curative management of ovarian cancer: Current issues and future directions
15. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies
16. Angiogenesis: New aspects relating to its initiation and control
17. Angiogenesis in cancer, vascular, rheumatoid and other disease
18. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
19. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-mall cell lung cancer tumors: Single agent and combination chemotherapy studies
20. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
21. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin
22. Markers of tumor angiogenesis: Clinical applications in prognosis and anti-angiogenic therapy
23. What, if anything, is an angiogenic factor?
24. Regulation of tumor angiogenesis by organ-specific cytokines
25. Angiogenesis: A dynamic balance of stimulators and inhibitors
26. Effect of host microenvironment on the micro-circulation of human colon adenocarcinoma
27. Geometric resistance and microvascular network architecture of human colorectal carcinoma
28. The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors
29. A systems approach to cancer therapy
30. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications
31. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
32. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation
33. The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCgamma
34. VEGF receptor signaling in tumor angiogenesis
35. The role of protein kinase C in the regulation of cell growth and in signalling to the cell nucleus
36. Multiple biological responses activated by nuclear protein kinase C
37. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction
38. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C
39. Inhibitors of protein kinase C and related receptors for the lipophilic second-messenger sn-1,2-diacylglycerol
40. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13] oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase C beta
41. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531
42. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor
43. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
44. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis
45. Identification of PKC-isoform-specific biological actions using pharmacological approaches
46. Enzymatic rationale and preclinical support for a potent protein kinase Cb inhibitor in cancer therapy
47. UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response
48. The Jak/Stat signaling cascade
49. Antiangiogenic effects of a protein kinase Cβ selective small molecule
50. Human tumor xenografts in athymic nude mice as a preclinical screen for anticancer agents
51. Absence of HeLa cell contamination in 169 cell lines derived from human tumors
52. Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma
53. Prognostic value of vasculatr endothelial growth factor in breast cancer
54. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39
55. The methodology of quantitation of microvessel density and prognostic vallue of neovascularization associated with long-term survival in Japanese patients with breast cancer
56. Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma
57. Serum VEGF levels in women with benign breast tumor or breast cancer
58. Angiogenesis as a target for breast cancer therapy
59. Molecular mediators of tumor angiogenesis: Enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer
60. Angiogenesis in ductal breat carcinoma. Comparison of microvessel density between primary tumor and lymph node metastasis
61. Clinical significance of angiogenic factors in breast cancer
62. Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E
63. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients
64. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
65. Doxorubicin gradients in human breast cancer
66. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer
67. The prognostic significance of angiogenesis in epithelial ovarian carcinoma
68. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer
69. Ovarian cancer patients with high CA-125 but no symptoms - Should antiangiogenic treatments be considered?
70. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth